IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 62.76

Change

+0.67 (+1.08)%

Market Cap

N/A

Volume

0.21M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.41 (+0.96%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.20%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+0.80 (+0.73%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.02 (+1.07%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.78 (+3.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.67 (+2.03%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.37 (+0.36%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.59 (+1.93%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.21 (+1.95%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.79 (+3.41%)

USD 6.89M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

-0.22 (-2.11%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

-0.22 (-2.11%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.71% 57% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.71% 57% F 84% B
Trailing 12 Months  
Capital Gain 3.85% 33% F 44% F
Dividend Return 1.20% 81% B- 19% F
Total Return 5.06% 43% F 35% F
Trailing 5 Years  
Capital Gain 44.06% 90% A- 69% C-
Dividend Return 7.26% 74% C 20% F
Total Return 51.32% 95% A 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.11% 71% C- 54% F
Dividend Return 7.12% 76% C+ 50% F
Total Return 1.01% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 18.47% 52% F 59% D-
Risk Adjusted Return 38.54% 71% C- 53% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike